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Abstract … 160 … 
 This essay begins by proposing that muscle weakness of old age from sarcopenia is due 
in large part to reduced capillary density in the muscles, as documented in  9 reports of aged 
persons and animals.  Capillary density (CD) is determined by local levels of various angiogenic 
factors, which also decline in muscles with aging, as reported in 7 studies of old persons and 
animals.  There are also numerous reports of reduced CD in the aged brain and other studies 
showing reduced CD in the kidney and heart of aged animals.  Thus a waning angiogenesis 
throughout the body may be a natural occurrence in later years and may account significantly for 
the lesser ailments (physical and cognitive) of elderly people.  Old age is regarded here as a 
deficiency state which may be corrected by therapeutic angiogenesis, much as a hormonal 
deficiency can be relieved by the appropriate hormone therapy.  Such therapy could employ 
recombinant angiogenic factors which are now commercially available.  
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              TEXT … 7229 … 5 06 15 
1.  Introduction  
 In the years before succumbing to a fatal illness (cardiovascular disease, malignancy, 
pneumonia, etc.), most older persons complain of several lesser ailments –  occasional memory 
lapses/pauses (senior moments) and muscle weakness.  I suggest that these symptoms of aging 
may share a common pathology – i.e., a deficient microcirculation secondary to the age-linked 
decline of angiogenic (AG) factors.  Loss of muscle strength is the main focus of this essay, 
while minor memory problems of old age are secondary here and akin to the more serious 
cognitive decline (senile dementias) discussed in previous papers. Ambrose  2012,  2013,  2015A  
 The physical and mental deterioration characterizing old age has been ascribed to the 
numerous causes. Comfort 12974, Hayflickl 1975, Kowald 1996, Weinert 2003, Duc 2014    In 1974, a reviewer 
commented that there seems to be one theory on aging for every published investigator. Marx 1974   
The various proposals have been considered under two broad groupings: developmental (genetic) 
versus stochastic (random) … with specific theories falling under one group or sometimes under 
both.  It is now generally assumed that most cases of aging are due to several deleterious 
influences.  Correcting one of them might slow or moderate the general deterioration.      
  The various theories of aging (e.g., longevity gene, somatic mutations, epigenetic 
modifications, stress, thymic atrophy, free radical toxicity, etc.) seem tenable but suggest no 
concrete means of therapy … or at least any measures readily available for general use now.  
However, practical therapeutic approaches are offered by theories which invoke a deficiency 
state – e.g., hormonal levels falling with age.  Another deficiency state is the age-linked decline 
of angiogenic growth factors -- the major concern of this paper.    
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 By way of background for this essay, the microcirculation throughout the body is 
commonly designated as capillary density (CD) and is determined in large part by local levels 
of angiogenic (AG) factors – e.g., vascular endothelial growth factor (VEGF), fibroblastic 
growth factor (FGF), and others.  The brain will be discussed briefly first, because data showing 
reduced CD there support the analogous reduction to be discussed later in muscles.  As 
documented in an earlier paper, reduced cerebral capillary density has been reported in the 
brains of aged people (5 reports), those with Alzheimer’s disease (5 reports), and also old rats 
and mice (13 reports). Ambrose 2015A:  Tables 2 & 3  See Footnote 1.  These data led to the 
Neuroangiogenesis Hypothesis (NAG hypothesis) advanced in that paper as one cause of 
impaired cognition in persons with senile dementias.   
 The levels of angiogenic factors  have not been reported in the brains of aged persons, 
but one recent study found diminished levels of VEGF in the parietal cortex of old rats. 
Viboolvorakul  2014   When specifically looked for, a comparable decline of AG factors in the aged 
human brain may likely be found, consistent with the above report on rats and comparable to 
lower levels in aged muscle -- as treated next.  My review of levels of CD and AG factors in the 
aging brain led to examining the literature for similar studies in the muscles of aged people and 
animals, where depressed levels have indeed been found.  This later review is the basis for 
presenting here a view of age-linked muscle weakness which can be termed the MAAG 
hypothesis (for muscle-associated angiogenesis) -- a corollary to the NAG hypothesis.     
 Muscle strength appears influenced directly not only by AG factors (via CD) but also by 
muscle stem cells and both secondarily by certain hormones.  The waning muscle mass in older 
persons reflects the age-related decrease in progenitor stem cells, which are acted upon by 
hormones (Section 3).  Considerable data indicate that the age-associated falling levels of various 
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hormones directly influence declining levels of AG factors in older persons (Section 4).  Matrix 
proteins (fibronectin, laminin, etc.) interacting with various growth factors may also affect 
muscle stability/strength via angiogenesis. Arthur 1998,  Sadoun 2003    
 This essay has two parts: Part I concerns angiogenic factors, stem cells, and hormones in 
the context of muscle weakness, while Part II suggests therapeutic options for relieving muscle 
weakness with angiogenic agents.  These are now commercially available in recombinant forms, 
and their use would seem comparable to that of various hormones in their respective deficiency 
states.   
 
                         Part I:  Decreased Angiogenesis in Muscles with Age      
2.  Muscle weakness and waning angiogenesis   
 In aged persons, muscle weakness and diminished exercise tolerance are commonly 
ascribed to a failing heart and/or diseased lungs – i.e., to a reduced level of oxygenated blood 
available to the body tissues. Wagner 2006  Atherosclerosis, strokes, injuries, and a sedentary life 
style also lead to muscle weakness due to a reduced skeletal muscle mass, termed sarcopenia.  In 
the elderly this condition is more conspicuous in the legs than in the arms and trunk, perhaps 
because the latter are being moved even when sitting. Borkan 1983: Table  2  Sarcopenia is defined as 
“appendicular skeletal muscle mass … being less than two standard deviations below the mean 
of a young reference group.” Baumgartner 1998   By age 80, in both sexes there is “a 30-50% decrease 
in skeletal muscle mass” due to loss in number of muscle fibers. Faulkner 2007  Sarcopenia is 
associated with reduced local CD and reduced levels of AG factors, as documented below.   
 
2.1.  Reduced CD and AG factors in skeletal muscles   
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 Five reports of reduced CD in lower limb muscles of elderly persons are presented in 
Table 1.  Four such studies in the skeletal muscles of aged laboratory animals are listed in Table 
2.  Lower levels of AG factors have been found in skeletal muscles of the aged – 4 reports in 
aged people (Table 3) and 4 in old animals (Table 4).  In animal muscle studies, experimental 
support for role of VEGF in maintaining CD comes from two opposite approaches: suppressing 
endogenous levels of VEGF or correcting low levels (enhancing angiogenesis) with exogenous 
VEGF.   
    
2.2.  Suppressing angiogenesis with  an antibody or an enzyme    
 Amaral et al. tested rats in which exercise training induced on three consecutive days was 
shown to increase CD in skeletal muscles.  Monoclonal VEGF neutralizing antibody was 
injected intraperitoneally on Day -1, +1, & +2 of the 3-day exercise protocol.  The CD (capillary 
intersections/mm2) in the tibialis anterior muscle on Day 3 was 129 in the control rats and 
reduced to 108 in the antibody-treated rats.  A comparable decline was found in the 
gastrocnemius muscle. Amaral  2001:  Fig. 5   
 Several groups of investigators have depleted VEGF throughout the gastrocnemius 
muscle of transgenic mice by the local injection of a recombinant cre recombinase adeno-
associated viral vector. Tang  2004,  Wagner  2006  Tang et al. found that this procedure reduced the 
expression of three isoforms of VEGF in the injected muscles.  Correspondingly, the local 
capillary density was reduced to 64% by week 4 and was 69% on week 8.   
 
2.3.  Enhancing angiogenesis with recombinant VEGF  
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 The opposite approach has involved administering growth factors to animals and 
measuring CD in leg muscles.  Rivard et al. created hind limb ischemia in both old and young 
rabbits, which were injected with recombinant VEGF on postoperative day 10 via the iliac artery 
of the affected limb.  On Day -10 (before injection) and Day 40 the average CDs (expressed as 
capillaries/mm2) in young rabbits were 170 & 280 (64%) and in old rabbits were 130 & 190 
(46%). Rivard 1999  Comparable results were obtained in similar experiments with mice.  
 While diminished local levels of AG factors and the resulting reduced CD may account 
directly for muscle weakness and sarcopenia, other biological processes may also be involved – 
e.g., a reduced presence of myogenic stem cells and diminished levels of various hormones.   
 
3.  Muscle weakness and waning muscle stem cells  
 In higher animals after birth, the maintenance and regeneration of skeletal muscles 
involve tissue-specific stem cells – a.k.a., myogenic precursor cells, progenitor cells, or satellite 
cells. Sieveking 2009   These reside adjacent to mature myocytes beneath the lambia propria and are 
quiescent until activated by muscle injury or exercise.  Either stimulus induces proliferation of 
the precursor cells and formation of nascent myotubules. Conboy 2002  This activation is under 
control of the Notch and related signaling pathways.  (Footnote 2)   
 During old age, the regenerative capacity of muscle declines because the stem cells 
become less activated via the Notch pathway. Conboy 2003,  Brack 2007,  Carlson 2008  Discussion of it is 
beyond the scope of this essay except for the following conclusion.  The various pathways 
responsible for muscle repair are regulated by “systemic factors” which change with age. Wagers 
2005, ;l;;Conboy  2005   These factors were not specified but likely include hormones.  For example, 
Sinha-Hikim et al. found that testosterone administered to elderly men increased the number of 
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muscle satellite cells. Sinha-Hikim 2006    Tateishi-Yuyama et al. “reported that the CD34-fraction of 
bone marrow stem cells” synthesize VEGF, bFGF, and Ang-1. Tateishi-Yuyama 2002  Thus muscle 
stem cells may provide paracrine AG factors in muscle areas.    
  Stem cells have been used therapeutically.  Tateishi-Yuyama et al. implanted bone 
marrow-mononuclear cells (including endothelial progenitor cells) into ischemic limbs of 
persons with peripheral arterial disease and noted new collateral vessel formation, as disclosed in 
angiograms.  The subjects reported increased pain-free walking times and reduced leg rest pain.  
Ischemic ulcers and gangrene were also lessened. Tateishi-Yuyama 2002 
  
4.  Muscle weakness and waning hormone levels  
 In a 1997 article entitled “The Endocrinology of Aging,” Lamberts et al. ascribed loss of 
muscle strength in aged persons to diminished levels of various agents -- insulin, thyroxine, and 
several other hormones: dehydroepiandrosterone, testosterone, estrogen, or growth 
hormone/insulin-like GH. Lamberts 1997  Of these, testosterone, estrogen, and thyroxine will be 
discussed below because of the abundant data showing that their actions on muscles and other 
tissues involve angiogenesis.  
 
4.1.  Androgens   
 An association between androgens and angiogenesis has been found in the prostate, heart, 
skeletal muscles, and brain of mice, rats, men, and even some song birds.    
 Castration of male mice resulted in a decreased VEGF content of ventral prostate tissue. 
Joseph 1997  The prostates of adult rats injected with dehydrotestosterone (DHT) showed a “a four-
fold increase in VEGF specific activity.” Sordello 1998  Numerous papers have reported that 
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androgens up-regulate VEGF in cultures of normal and malignant human prostatic cells. Joseph 
1997,  Sordello 1998,  Eisermann 2013    
 In a rat model of myocardial infarction (ligation of a coronary artery), castration of males 
impaired the expression of VEGF in the ischemic myocardium. Chen 2012a   Here  testosterone 
replacement therapy promoted angiogenesis in the myocardium, as measured 28 days after 
infarction.  In a mouse hind limb ischemia model, castrated male mice showed a reduced CD in 
the affected limb but a restored vacularization upon treatment with an androgen. Sieveking 2010  The 
authors concluded that androgens exerted a proangiogenic effect which depends on VEGF and 
involves the mobilization of angiogenic-progenitor cells to sites of ischemia. Sieveking 2009, 2010    
 In older men, exogenous testosterone increases skeletal muscle mass, thus reversing 
sarcopenia. Uban 1995,  Bhasin 1996, Sih 1997,  Snyder 1999,  Ferrando 2002,  Wittert 2003,  Sinha-Hikim 2006, Atkinson 2010,   
 The seasonal acquisition of song capacity in some canaries and finches is related to rising 
levels of testosterone, which trigger neuronal production in the higher vocal center (HVC). Chen 
2013  This is preceded by a burst of local endothelial cell division and angiogenesis, as evidenced 
by a rise in VEGF mRNA and VEGF protein.  Cultures of canary HVC endothelial cell increased 
their rate of division in response to VEGF but not to testosterone.  This suggests that in the 
brains of these birds testosterone induces the paracrine production of VEGF.    
 
4.2.  Estrogens    
 Morales et al. examined several human umbilical endothelial cell culture systems and 
found that 17β-estradiol promoted migration and proliferation of the cells and formation of 
capillary-like networks. Morales 1995   The authors wrote that estradiol “enhances the multiple 
components of angiogenesis activity in vitro” and may augment the action of angiogenic growth 
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factors in tissues with either high estrogenic content or abundant estrogen responsiveness.  This 
association may account for women having a higher incidence of various vasculitic diseases.  
The effect of 17β-estradiol modulating angiogenesis was also studied by others. Rubanyi 2002  
 
4.3.  Thyroid hormones  
 These hormones induce neovascularization in various settings – muscles, the heart, brain, 
and tumors. Luidens 2010, Zhang 2010   As outlined by Liu et al., the process begins for thyroid 
hormones at cell surface receptors on endothelial and muscle cells (e.g., integrin αvβ3).  The 
hormone signal is transduced via this receptor for the transcription of angiogenic-relevant genes, 
which leads to the synthesis and secretion of AG proteins. Liu 2014   Mousa et al. wrote that the 
hormone and its analogues modulate the “activities of multiple vascular growth factors receptors 
and their ligands” – thus  linking this hormone to angiogenesis. Mousa 2014   Four experimental 
examples of thyroid-related angiogenesis follow.    
 Heart failure (“cardiac microvascular impairment”) was produced in mice within a year 
of being fed propylthiouracil (PTU) to make them hypothyroid.  Chen 2012  Triiodothyronine  (T3) 
administered for three day induced significant capillary growth in the heart. 
 The forebrain regions of thyroidectomized rats showed decreased CD.  Thyroxine (T4) or 
a thyroid analog “normalized” the blood vessel density. Schlenker 2008   Decreased brain 
angiogenesis (a “reduced complexity and density of microvessels”) was found in young rats 
treated with PTU for 21 days to induce hypothyroidism. Zhang 2010 
 The severe mental retardation in cretinism has generally been ascribed to the direct effect 
of hypothyroidism on CNS neurons and myelination. Zhang 2010  But, as the above examples in rats 
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suggest, the retardation might result primarily from a deficient cerebral angiogenesis and 
secondarily from defective/deficient neurons.   
 In summary, the above studies raise the possibility that the deficiency of one or more 
relevant hormones may lead to sarcopenia or otherwise impair function because of reduced 
angiogenesis.    
 
5.  Enhanced Muscle strength and physiologic angiogenesis  
   Exercise induces increased CD and the release of AG factors in the muscles of people 
and animals. Gavin 2007,  Lloyd 2003   See Table 5.  This could be termed physiologic angiogenesis in 
contrast to pharmacologic/therapeutic angiogenesis, discussed later in Part II.  Such AG factors 
may exert a beneficial paracrine effect on endothelial cells and perhaps on myogenic progenitor 
cells and thus help reverse sarcopenia.  Upon entering the circulation, the factors could stimulate 
angiogenesis in distant sites –  i.e., have an endocrine effect.  Gerontologists have long 
advocated walking to help maintain/improve mobility (muscle strength) and to benefit the 
cardiovascular system -- possibly adding a year or so of life. Pafenbarger 1986  
 Educators have also encouraged walking, since this has been thought to enhance learning 
in people and mice. Colcombe 2004,  van Praag 1999  A recent paper by Strothart et al. suggests that any 
benefit in cognition from exercise may be a placebo effect, while an article by Hillman et al. 
confirms “the importance of physical activity on mental development.” Strohart 2014, Hillman 2014   
Exercise has an immediate effect of increasing circulation in the brain from vasodilatation, but it 
may provide a long term effect by increasing cerebral capillary density.  Isaacs et al. observed 
increased angiogenesis in the rat cerebellum after it underwent vigorous physical activity. Isaacs 
1992   Ding et al. reported that aged rats run daily for three weeks in a treadmill showed increased 
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cerebral CD and elevation of VEGF mRNA ( 27%) and VEGF protein ( c.20%) in the motor 
cortex and striatum.  Ding 2006: Fig. 4 & 6    
 Table 5A shows increased local CD and/or elevated levels of VEGF from 21 reports on 
exercised muscles in people and animals.  Human subjects (15 studies) exercised on a bicycle 
ergometer or single leg extension device, while small animals (6) were run on a circular 
treadmill.  Table 5B shows 10 studies involving electrical stimulation with electrodes implanted 
into the flexor muscle of one leg of a rat or rabbit.  In both types of experiments, biopsies were 
taken from the flexor muscles of animals or the vastus lateralis or other lower muscle of human 
subjects.  Experimental and control biopsies were examined for evidence of increased vascularity 
(CD) and/or for levels of VEGF protein and VEGF mRNA.  Representative of these studies on 
human subjects are the four following reports – the first two showing increased CD in muscles 
with exercise and the last two illustrating elevated muscle levels of VEGF with exercise.  
 Denis et al. examined two groups of men (G20: age 22 ±3 yrs and G60: age 62 ±4 yrs) 
who trained for 20 weeks pedaling a bicycle ergometer at 75 rpm for 60 min/day, 4 times a week.  
Needle biopsies were obtained from the vastus lateralis muscle before and after training.  
Capillary density (cap/mm2) in the G20 group increased from 316 ±42 to 396 ±73 (25%).  The 
CD in the G60 group rose from 308 ±48 to 409 ±55 (32%). Denis 1986 
 Gavin et al. observed increased capillarization (“capillary contacts” = cc) and levels of 
VEGF mRNA in the vastus lateralis in both young men (19-30 yrs) and old men (56-74 yrs) 
after 8 weeks of aerobic exercise.  Capillary density (cc/mm2) in young men rose from 264 ±16 
to 341 ±29 (29%) and in old men from 303 ±28 to 350 ±63 (15%). Gavin 2007     
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 Richardson et al. subjected young males to the exercise stimulus of a single leg knee-
extensor ergometer.  Biopsies of vastus lateralis muscle revealed VEGF mRNA levels of 0.38 
±0.04 before exercise and 7.1 ±1.8 one hour afterwards. Richardson 1999 
 Gustafsson et al. followed healthy males who underwent 8 weeks of a one-legged knee-
extension program.  One day after the 7th training session, muscle biopsies showed a two-fold 
increase in both VEGF mRNA and VEGF protein expression. Gustafsson 2001, 2002  
 Relevant to this essay’s concern with aging is that the increased CD and elevated levels 
of AG factors were often less in the challenged muscles of old animals and elderly people than 
in those of their younger counterparts.  For example, Adolfsson et al. found that exercise 
increased CD in young rat muscles from a baseline value of 460  710 (54%) and in old rats 
from 395  484 (23%). Adolfsson 1981   The same trend was found in several others reports, 
including that of Gavin et al above, where the young human subjects showed a 29% increase and 
the elderly only a 15% increase. Coggan 1992, Ryan 2006, Gavin 2007.   
 
6.  Summary of Part I and an Overview of Angiogenesis in Muscles during Aging 
 The above review from the literature on muscle physiology is the basis of the muscle-
associated angiogenesis hypothesis.  Tables 1 & 2 of this essay present data from 9 reports 
showing that CD declines in the skeletal muscles of both people and animals with age.   These 
reports are complemented by similar data from other areas of the body.  In a previous publication 
are summarized 18 studies showing reduced CD in the aged brains of people and animals. Ambrose 
2015A   To that list can be added two similar recent reports in rat brains. Desjardins 2014., Viboolavorakul 2014    
Age-lined reduced CD has also been found in rat kidney Kang 2002: Table 2, #7, in  the subendothelium 
of rat heart Iemitsu 2006, and in  sponges placed in wounds of mice. Sadoun 2003    Thus there are 32 
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reports of reduced levels of CD in various organ systems (and sponge inserts) of aged subjects 
and animals.    
  Tables 3 & 4 present data from 7 reports showing reduced levels of AG factors in the 
muscles of aged people and animals.  Reduced levels of AG factors have also been found in the 
brain (left parietal cortex) of aged rats Viboolvorakul 2014, in the heart (left ventricular wall) of aged 
rats Iemitsu 2006, and in two reports of sponge implants in mice. Reed 1998, Sandoun 2003    Thus there are 
11 reports of depressed levels of AG factors in various organs (or implants) of aged persons and 
animals.  These two sets of data (32 + 11) strongly suggest that reduced CD and lowered levels 
of AG factors occur throughout the body in aged persons and in those old animals studied.   
 But the decline of CD and AG levels may not be uniformly expressed throughout the 
body.  To date, there is no documented concordance between muscle weakness and cognitive 
decline in people, indicating either a differential decline in each organ system or that other 
influences may affect aging in them.  But correcting one influence (e.g., a reduced CD) 
theoretically might benefit an aging brain or tired old muscles or both.  Finally, mankind isn’t 
helped by another theory on aging unless it offers tangible therapeutic options, which the 
angiogenesis hypotheses on aging do.  These options are discussed below at length in Part II.    
 
     Part II:  Therapy of Muscle Weakness 
7.  Treatment of muscle weakness by therapeutic angiogenesis       
 Seeking to delay the decline in health associated with aging, millions of Americans 
consume various vitamins and sundry supplements -- e.g., chondroitin sulfate & glucosamine, 
hormones (testosterone, thyroxin), fish oil, ginkgo biloba, etc.  Others have received periodic 
injections of anti-aging agents -- e.g., B12, gonadal extracts, procaine HCl, etc.  Theoretically, the 
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process of aging should be slowed by certain biological agents.  In 1974, Alex Comfort listed the 
following:  radioprotectants, protein synthesis inhibitors, anti-crosslinking agents, lysosome 
stabilizers, antioxidants, immunosuppressants, and hormones. Comfort 1974    To these hypothetical 
agents now might be added amyloid destabilizers, anti-telomerases and, according to this essay, 
readily available ones -- e.g., recombinant angiogenic cytokines.   
 Attempts at therapeutic angiogenesis began over twenty years ago in animals with an 
experimentally induced ischemic myocardium (e.g., by ameroid constriction of the left 
circumflex artery) or ischemic skeletal muscles (e.g., ligation of femoral artery in hind limb). Banai 
1991,  Baffour 1992   First phase trials in patients with myocardial insufficiency soon followed. Henry 
1998,  Schumacher 1998   Studies in both animals and people, as noted below, have yielded practical 
information about angiogenic factors (e.g., safe levels) applicable to the potential treatment of 
muscle weakness of the aged -- hence the following brief review of cardiac and muscle studies.    
 
7.1.  Cardiac studies in animals & people  
 Lin et al. described cardiac sarcopenia in mice. Lin  2008   Myocyte numbers decrease while 
there is increased fibrosis, accounting for the heart generally becoming thicker with age.  Lin et 
al. suggest that “cardiac sarcopenia may explain, in part, why elderly patients respond poorly to 
cardiovascular events.” 
  In recent therapeutic studies on the heart, either of two classes of agents was introduced 
into the ischemic myocardium of animals and later of people – the recombinant protein of 
various growth factors or their genes (naked DNA as a plasmid or via a viral vector).  Several 
investigators have discussed these two approaches and have concluded that “protein therapy is 
closer to practical use than gene therapy.” Simons 2000,  Post 2001  Most preliminary papers reported 
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favorable results in treated patients.  But a decade later, reviews concluded that neither of these 
two approaches showed unequivocal clinical benefit in double-blind, randomized placebo-
control trials. Khurana 2005, Simons 2005   “Inadequate duration of exposure to the angiogenic agent” 
may have limited its effectiveness. Gupta 2009  Another weakness in the clinical trials may have 
been the assumption that a single factor would be effective. Zhang 2009  These two considerations 
will be discussed later.   
   
7.2.  Skeletal muscle studies in animals   
 Ligation of a femoral artery in the hind limb of laboratory animals simulates lower leg 
muscle weakness in older persons.  Table 6A summarizes 5 such studies in mice, rats, and 
rabbits showing increased hind limb vascularity ( CD) with angiogenic treatment.  Table 6B 
concerns 8 reports showing increased microcirculation (and healing) after the application of AG 
factors  in other experimental situations -- bone graft, wound repair, and sponge/gel implants. 
 
7.3.  Skeletal muscles studies in people    
 Post et al. noted the scarcity of clinical studies using AG factors in persons with 
peripheral vascular disease. Post 2001  Nor have I found any reports examining the effect of 
recombinant (r) angiogenic factors on the muscle weakness and sarcopenia of elderly persons.  
 The closest work is that by Lederman et al. showing the benefit of recombinant FGF-2 on 
intermittent claudication (IC). Lederman 2002  Patients with limited walking tolerance caused by 
infra-inguinal atherosclerosis received bilateral femoral artery infusions of three types:  1) 
placebos on Days 1 & 30, 2) rFGF-2 on Day 1 & placebo on Day 30, 3) recombinant acidic FGF 
on both Days 1 & 30.  Exercise tolerance was measured using a standardized Gardner treadmill 
17 
 
protocol.  On Day 90 walking times in minutes were found to be increased from baseline values 
in the three groups as follows:  0.97 min (5.32  6.29), 1.95 min (5:15  7.10), and 1.77 min 
(5.81  7.58), respectively.  Two infusions of r-FGF-2 thirty days apart (the 3rd treatment type) 
appeared less beneficial than a single injection only because that group had a higher baseline 
value (5.81 min.).  The final assessment included 174 patients.  Sixteen others were eliminated 
because of adverse events, including renal abnormalities (proteinuria).  The maximum tolerated 
dose was 30 µg/kg.  Higher levels induced acute hypotension.  This study is valuable for 
highlighting the placebo effect and identifying untoward effects from rFGF-2. 
  
8.  Angiogenic factors    
 Of primary concern for treating muscle weakness in the aged would be selecting a 
therapeutic regimen.  Simons concluded that in previous cardiac studies the choices of AG 
agents had “little physiological rationale” but instead rested on the availability of certain growth 
factors and the selection of those with less risk of side effects. Simons 2005  Again, useful 
information for selecting a particular treatment may be gleaned from the past clinical and 
laboratory studies -- notably, safe levels of these agents for people.    
 
8.1.  Single agents   
 Human trials to date have employed single agents – e.g., VEGF Vale 1999, Gibson 1999,  Henry 
1999, 2003, FGF-1 Schumacher 1998, and FGF-2.  Laham 1999, 2000,  Unger 2000   These and other factors are 
listed below, followed by brief abstracts of animal studies illustrating their use in therapeutic 
angiogenesis.   
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8.1.1.  VEGF   
 Of the six members of this family, three (VEGF-A, -B, & -E) and PIGF (placental growth 
factor) act preferentially on vascular endothelial cells.  VEGF “maintains its position as the most 
critical driver of vascular formation.” Yancopoulos 2000    VEGF-1 and VEGF-D  NC have the 
strongest AG effect on skeletal muscles. Rissanen 2003   
 Takeshita et al. prepared rabbits with ischemia in one hind limb and injected a 500-5000 
µg bolus of VEGF165 over one minute in the ipsilateral iliac artery on Day 10 after ligation of the 
femoral artery.  They found increased vascularity in the muscles of the treated leg by Day 30 but 
no additional increase later. Takeshita 1994  Rivard et al. followed the same procedure using a 500 µg 
bolus of VEGF165 and found increased capillary density on Day 40 after surgery in treated 
rabbits, both young and old but somewhat less in the old ones. Rivard 1999: Fig 5G   The latter authors 
regarded VEGF as “the pivotal cytokine deficiency responsible for impaired angiogenesis.”  
 
8.1.2.  FGF  
 Of the 23 or so members of this group, FGF-1 (acidic FGF, aFGF) and FGF-2 (basic 
FGF, bFGF) are prototypes which are “preferentially implicated in angiogenesis.” Friesel 1995,  Post 
2001  The most studied member, bFGF, has a broad spectrum of target cells – endothelial cells, 
smooth muscle cells, and fibroblasts. Friesel 1995      
 Baffour et al. examined bFGF in the ischemic hind limb rabbit model.  Three groups of 
rabbits received various intramuscular injections daily for 14 days – 17 rabbits being saline 
controls, 15 receiving 1µg bFGF, and 15 receiving 3µg bFGF.  Day 14 angiograms of the treated 
limbs showed CDs in the three groups, respectively, of 36 ±10, 69 ± 15, and 108 ± 7. Baffour 1992  
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These data plus related work by Yang et al., Witzenbichler at al., and others are listed in Table 
7A. Yang 1996,  Witzenhichler 1998  
 
8.2.  Agents in synergism   
 Various investigators have assumed that the clinical administration of a single AG factor 
(e.g., VEGF) would be ineffective, since several or many may be necessary for a coordinated 
angiogenic response. Cao 2003,  Zhang 2009  This synergism has been observed in several in vitro 
studies.  Endothelial cells cultured within three-dimensional collagen gels and treated with 
VDGF and bFGF showed a synergistic effect on proliferation and cord formation – as additive 
effect greater than that of each agent alone. Pepper 1992, Goto 1993  Other examples of synergism are 
given below.   
 
8.2.1.  Angiopoietin    
 There are the four members of this family.  Generalizing from many studies, 
Yancopoulos et al. wrote that Ang-1 acts synergistically with VEGF to promote vessel stability, 
while Ang-2 has the opposite effect. Yancopoulos 2000  Lloyd et al. cautioned that the ratio present 
may be crucial. Lloyd 2003  
 Peirce et al. examined the coordinated role of VEGF165 and Ang-1 in dorsal skinfold 
window chambers surgically positioned on the backs of rats five days before Day 0 of the study.  
Slow release alginate beads contained either VEGF, Ang-1, or neither agent.  A single bead was 
inserted in the visual field of each chamber on Day 0 and replaced on Day 7.  The chamber with 
a VEGF bead on Day 0 and control beads on Day 7 showed increased CD on Days 7 and 14 but 
not 21.  The chamber with VEGF bead on Day and Ang-1 on day 7 showed increased CD on 
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Days 7, 14, and 21, thus indicating that Ang-1 “promote[d] vessel stabilization and maturation.”  
Peirce 2004  
 
8.2.2.  Platelet derived growth factor.   
 There are three isoforms of PDGF:  AA, AB, and BB.  In an ischemic hind limb model in 
rats, Zhang et al. found that PDGF-AB + FGF-2 yielded stable capillary growth, while PDGF-
AA + FGF-2 did not. Zhang 2009    
 Cao et al. used a Matrigel pellet model, in which heparin-Sepharose beads containing one 
or two factors were inserted subcutaneously into mice and after two weeks retrieved and 
examined microscopically for vessel formation. Cao 2003  They found that PDGF-BB + FGF-2 
elicits angiogenesis greater than the sum of the separate effect of both agents, while PDGF-BB + 
VEGF produced only a slightly additive effect to that of either one alone.  Since endothelial cells 
delineate the capillary lumen, while mural cells (pericytes and smooth muscle cells) stabilize it, 
the authors inferred that these two separate functions are controlled by different AG factors – the 
former by FGF-2 or VEGF and the latter by PDGF.   The above four reports show that stable 
angiogenesis was produced with the appropriate combinations of factors.  
 
8.3.   Further considerations   
 Most clinical trials of the past several decades have employed only one agent.  Single 
factor therapy for treating myocardial insufficiency has occasioned few or no complications. Henry 
2000,  Celletti 2001,  Epstein 2001  But Yancopoulos et al. and other investigators have warned that the 
administration of “a single growth factor to reconstitute a vascular bed is somewhat naive and 
even misguided.” Yancopoulos 2000,  Henry 2000   Here the authors may have had in mind VEGF’s 
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original name, “vascular permeability factor,” the risk of internal bleeding, and the stabilizing 
effect of Ang2 on VEGF.  While this risk must be kept foremost in mind, an additional 
consideration explained below may qualify the above warning in the case of muscle weakness of 
the aged.     
 In older animals and people the levels of certain angiogenic factors are reduced in various 
tissues (muscle, brain, heart), but there is no evidence that all factors involved in producing the 
coordinated response of angiogenesis are reduced equally.  Returning a deficient one to the 
earlier, youthful level might be sufficient if other participating factors are still available in tissue 
sites.  Based on this assumption and in lieu of the few complications reported in numerous 
clinical trials with VEGF and FGF, replacing a single waning factor might be safe and effective 
in ameliorating general muscle weakness of old age.  But this consideration still acknowledges 
the theoretical risk from long term treatment – i.e., longer than past clinical trials.    
 
9.  Various routes for therapeutic angiogenesis    
 Studies aimed at returning AG factors in muscles to normal, healthy levels would likely 
continue for many years – for the rest of an aged person’s life. Dor 2002, Annex 2005, Ferrara 2005, Gupta 2009,  
Roy 2010   If therapeutic angiogenesis were found to be effective in preliminary trials, then the wide 
spread use of this method would be most feasible if it involve the self-administration of the AG 
factor.  Intravenous and intramuscular routes are not convenient and disliked by many subjects.  
Agents ingested would be destroyed through acid/enzymatic breakdown in the gastro-intestinal 
tract.  Alternative routes involving absorption via the nose, lung, cheek, or tongue avoid the GI 
destruction and first pass metabolism in the liver and would be preferable to injections by most 
subjects.  (Ophthalmic, vaginal, and rectal routes are not considered here.) 
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 An obstacle at the four alternative sites is the absorption of macromolecules across lipid-
rich epithelial cell membranes into the circulation.  Such absorption is inversely related to a 
protein’s molecular weight – i.e., being less for large proteins, such as bFGF (17 kDa) and VEGF 
(42 kDa).  Molecular weights are given for most of the AG factors noted below.  Ways of 
overcoming the weight problem are discussed in Section 10.1.   
 
9.1.  Nose   
 Some sense of the absorption of various size macromolecules across mucous membranes 
into the circulation can be gleaned from the following examples.  Intranasal (i.n.) administration 
of oxytocin (1.0 kDa) led to its appearance in the plasma for up to two hours. Gossen 2012, Striepens 2013  
Numerous investigators have determined blood levels of immunoreactive insulin given by this 
route. Pontiroli 1989: Table 1   Insulin (5.8 kDa) administered i.n. reduced blood glucose levels, thus 
inferring the hormone’s bioavailability in the systemic circulation. Pontiroli 1992  In normal subjects, 
an i.n. spray of insulin plus Na glycogluconate produced a serum insulin level 4-times higher 
than a spray with insulin alone. Pontiroli 1987: interpr. from Fig. 1  Thorne et al. found rising levels of [125]-
insulin-like growth factor-1 (7.65 kDa) in the blood of rats 23 minutes after i.n. treatment.  At 21 
minutes the level of the above ILGF-1 was 0.48 nM in the blood and 0.15 nM in the deltoideus 
muscle. Thorne 2004: Table 1  Vitkun et al. delivered interferon β-1a (20 kDa) by nasal spray to male 
subjects and found 20% bioavailability in blood samples. Vitkun 2004  The possible administration 
of AG factors (17-45 kDa) intranasally to senile dementia patients was raised in two earlier 
papers.  The use of a tobacco-free snuff was suggested there. Ambrose 2013, 2015A   
 
9.2.  Lungs    
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 The potential advantages of pulmonary delivery of macromolecular proteins are the 
lungs’  large absorptive area, extensive vasculature, easily permeable membrane, and low 
enzyme activity Patton 1992,  Liu 1993  Wigley et al. administered insulin to diabetic patients during a 
5-minute nebulization period and found that 10% had been absorbed into the plasma. Wigley 1971  
Liu  et al. reported that intratracheal  instillation into rat lungs of the sodium dimer (11.6 kDa) or 
the zinc hexamer (34.8 kDa) of insulin led to the drug’s absorption as reflected in reduced blood 
glucose levels.  The exact form of insulin (monomeric or multimeric) in the blood was not 
determined.  The effect on blood glucose levels was similar whether the insulin preparation was 
entrapped in or merely accompanied by liposomes.  Aerosol administration was judged to yield 
“comparable” results. Liu1993   
 
9.3.  Buccal cheek   
 The buccal mucosa is less permeable than the nasal mucosa, but most elderly subjects 
would probably prefer the former as a therapeutic route. Merkle 1991  Three types of adhesive buccal 
vehicles provide intimate contact with mucous epithelium:  tablets, viscous gels, and patches. 
Merkle 1991  Boddie et al. employed buccal tablets made of muco-adhesive polymers, which protect 
against degradation by peptidases in the saliva. Boddie 1990    
 I have not found articles about enhancing absorption of AG factors with various 
adjuvants, but this approach is suggested by positive results of studies on other large molecules.  
Buccal adjuvants have included bile acids, fatty acids (e.g., myristate), and sugar esters. Merkle 1991   
Nakada et al. reported that deoxycholate, turoglycocholate, quillajasaponin, myristate, and sugar 
esters promoted absorption of human calcitonin (3.4 kDa) via buccal mucosa of rats. Nakada 1988  
Merkle et al. cited studies with the above adjuvants showing increased buccal and sublingual 
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absorption of the following proteins:  oxytocin (1 kDa), calcitonin (3.4 kDa), insulin (5.8 kDa), 
interferon (17 kDa), etc.  For example, 5% Na glycocholate added to insulin via buccal route  
25.5% of bioefficiency of the same dose of insulin given i.m. Aungst 1989   
 
9.4.  Tongue   
 The sublingual mucosa of the tongue underside is only 100-200 µm thick, has fewer cell 
layers than the buccal mucosa, and is non-keratinized – all favoring better absorption. Shojaei 1998  
In 1972 Sister Philomena Earle prepared 10 mg, I inch diameter tablets containing insulin HCl 
(5.8 kDa) along with a binder and vasodilator (neither defined) for placement on or under the 
tongue.  Using the tablet, she noted “a definite hypoglycemic reaction within 10 minutes” and a 
blood glucose estimate of 48 mg/ml. Earle 1972  No baseline data were provided.  Aungst et al. 
determined the absorption efficiency of insulin given by different routes to that by IM injection.  
The rank order of absorption was rectal >nasal >buccal >sublingual.  Inclusion of Na 
glycocholate to the insulin greatly increased absorption with the nasal route being the highest at 
46.8% and sublingual being 12%. Aungst 1988   
 
10.  Other issues in therapeutic angiogenesis        
 Of theoretical concern is whether exogenously administered AG factors could correct a 
local deficiency in muscles.  Affirmative evidence is present in Table 6A, which outlines five 
reports showing increased CD in the ischemic hind limbs of lab animals injected  IV, IM, or 
subcutaneous with VEGF or bFGF.  At issue is whether AG factors administered via the 
alternative routes (e.g., nasal, etc.) can pass into the circulation for access to distant muscles.   
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10.1.  Absorption of AG factors   
  In spite of their large size, perhaps AG factors (17-45 kDa) can be modified to become 
more transferable without losing funtionality.  Addition of methyl groups renders large molecule 
more lipophilic and thus more absorbable. Katrusiak 2011,  Gazdik 2014   
 Surfactant enhancers in the form of various bile salts, etc. may facilitate this transfer. 
Gordon 1985, Aungst 1988, Wearley 1991, Lambert 2007  For example, Daugherty et al. administered recombinant 
methionyl human growth hormone (ca. 20 kDa) via the nasal mucosa of rats.  The bioavailability 
in blood was 1% but rose to 7-8% in combination with bile salt sodium glycocholate. Daugherty 1988  
But these permeation enhancers may cause irreversible damage to mucosal cells. Gordon 1985   
 Polycationic materials (poly-L-arginine/lysine) and chitosan may also enhance absorption 
of macromolecules.  For example, in rat nasal studies, Miyamoto et al. found that adding poly-L-
arginine to a recombinant human granulocyte colony stimulating factor (rhG-CSF = 20 kDa) 
increased its bioavailability to 10%. Miyamoto 2001   However, such enhancers may also be toxic to 
mucosal epithelium.   
  
10.2.  Sustained treatment   
 Since the lesser ailments of old age developed over many years, it seems unlikely that 
single bolus therapy could be effective.  Treatment may need to be continuous and life-long. 
Many months may be required before beneficial clinical results become evident.  In human trials 
sustained release delivery of an agent may be achieved with multivesicular liposome 
(DepoFoam). Angst 2006   Alginate capsules and nanoparticles have been used in various studies. 
Strand 2002,  Peirce 2004, Roy 2010   
 The half-life of a protein in the circulation is determined by plasma proteases. McGonigle 2012   
Takashita et al. reported unpublished data of N. Ferrara et al. listing the half life of VEGF as less 
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than six minutes. Takashita 1994: 667  Protection of exogenous therapeutic agents can be obtained 
using liposomes and certain polymers. Boddie 1990   According to Katre et al., the free form of 
Insulin-like Growth Factor-1 survived in blood for less than one day but when incorporated into 
liposomes was sustained there for 5-7 days. Katre 1998  
 
10.3.  Side effects   
 Treatment continued over many years raises the threat of untoward mitogenesis inducing 
“angiogenic diseases”  -- e.g., tumor growth, diabetic retinopathy, polyarthritis, psoriasis, etc. Jain 
1997, Epstein 2001, Carmeliet 2003   Also, there has been concern that angiogenic therapy may promote the 
growth and rupture of atheromatous plaques leading to angina and myocardial infarcts.  Flugelman 
1993,  Kornowski 2000, Simons 2000,  Celletti 2001,  Moulton 2001   Recognizing untoward side effects is one purpose 
of clinical trials.  Finding ways to avoid and correct them is the later challenge.   
 
11.  Summary of Part II    
  In contrast to Part I of this essay, which focused on age-linked decline of AG factors 
with aging, there are the numerous studies in regular (not aged) mice and rats showing that levels 
of endogenous VEGF are increased in the immediate areas of experimentally generated cerebral 
infarcts or surgically induced focal cerebral ischemia. These studies were identified in references 
#130-138 in an earlier paper. Ambrose  2015A    Thus under some circumstance, angiogenesis is 
naturally induced locally.   
 There is a growing consensus that the “induction of angiogenesis is a promising 
therapeutic approach … to improving vascular function … in aging patients.”  Lähteenvuo 2014.   
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This expectation has not yet been realized for relieving weakened muscles of aged persons but 
has been amply demonstrated in laboratory animals.  Various angiogenic factors administered to 
ischemic hind limbs of mice, rats, and rabbits have produced increased vascularity in the muscles 
there (Table 6A).  Local application of AG factors to bone transplants, surgical wounds, and 
inserted sponges have likewise led to increased local vascularity (Table 6B).    
 The most impressive support to the idea of therapeutic angiogenesis has been in the 
brain.  Discussed elsewhere are the clinical studies by Harry S. Goldsmith, who transposed the 
intact pedicled omentum from persons with Alzheimer’s disease (AD) onto the surface of their 
brain. Ambrose  2015A,  Goldsmith  2014  These pedicles, which contain high levels of VEGF, release this 
factor onto the cerebral surface, where it is absorbed into the parenchyma. Zhanga 1997   Goldsmith 
recently reviewed 25 such operations on advanced AD patients and reported that six showed no 
improvement, ten showed slight improvement, and “nine demonstrated marked cognitive 
increases.” Goldsmith 2014   Of concern here is whether the positive results Goldsmith obtained in 
some AD patients with omentum grafts can be replicated for muscle weakness of old age by the 
administration of angiogenic factors.   
 As discussed earlier in Part I, muscle weakness from age-associated sarcopenia may have 
one or more possible causes -- 1) waning angiogenesis, 2) the temporal decline of muscle stem 
cells capable of “life-long maintenance and repair of myofibrils,” Carlson 2008   and 3) a deficiency 
of certain hormones (e.g., testosterone).   In spite of an incomplete understanding of the interplay 
of these possible causes, evidence supports considering the treatment of the muscle weakness of 
old age with therapeutic angiogenesis.    
 Edelberg and Reed began an article in 2003 with “Angiogenesis is impaired in aged 
tissues.”  Edelberg  2003  Another review like the present essay reaffirming this well documented 
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observation would seem unnecessary except for the fact that therapeutic angiogenesis has yet to 
be pursued in the relief of the lesser ailments of old age and the senile dementias.   
 
12.  Conclusions 
 In this essay, old age is viewed as a deficiency state in which muscle weakness and 
memory loss may be due in part to a reduced microcirculation secondary to the age-linked 
decline of angiogenic factors.  Waning stem cells and lower hormone levels may also exert a 
weakening effect on muscles via diminished angiogenesis. Senile dementias may be a long term 
consequence of the decline of angiogenic cytokines in the brain along with other possible 
influences.  This general decline is analogous to that of certain hormones whose blood and tissue 
levels fall with age.  Again, other influences besides a waning angiogenesis may also contribute 
to aging.  But correcting one influence (e.g., a reduced CD) may delay symptoms and signs of 
aging. 
 Therapeutic angiogenesis with recombinant AG factors seems an appropriate treatment to 
be considered for the lesser ailments of old age and also senile dementias and would be 
equivalent to administering testosterone, thyroxin, etc. to persons with the corresponding 
hormonal deficiencies.   The beneficial effect of these agents may continue up to the time when 
other pathologies intervene, leading to death.   
      End 
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FOOTNOTES 
 Footnote #1.  Riddle et al. summarized three decades of studies on age-related changes in 
cerebral capillary density in human subjects and rats.  They listed 14 reports of decreases and 7 
of no decreases. Riddle 2003  An explanation of the latter results may be tissue shrinkage in aged 
brains, which was discussed in a previous paper. Ambrose 2015      
 Footnote #2.  Notch refers to receptor proteins in the wall of cells enabling two adjacent 
ones (e.g., myogenic stem cells) to interact mechanically.  The name derives from notches in the 
wings of mutant fruit flies.  Various notched phenotypes were correlated with mutant loci in the 
flies’ chromosome. Morgan 1917  A gene homologous to the Notch gene in Drosophila was found in 
patients with lymphoblastic leukemia. Ellisen 1991  The name Notch has subsequently been applied 
to a genetic pathway system later found in myogenic precursor cells of higher animals. 
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Table 1.  Reduced Capillary Density in Muscles of Young vs. Aged Persons 
 
            
  Young       Aged 
 1.  Coggan 1992, Table 3  
      lateral gastrocnemius               24 ± 1 yrs.                               64 ± 1 yrs. 
      --  capil./mm2, male   308 ±16   228 ± 13 
      --  capil./mm2, female   328 ± 19   248 ±12 
 
2.  Proctor 1995, Table 3 
     vastus lateralis               21-30 yrs.                                51-62 yrs. 
     --  capil./mm2    419 ± 87                         390 ± 41 
     --  capil. contact/fiber IIA & IIB      5.0 ± 0.9           3.9 ± 0.8 
 
3.  Chilibeck 1997, Table 3           
      lateral gastrocnemius                                25.9 yr., mean                         66.9 yr., mean  
      --  capil./mm2    295 ±105   245 ± 50        
 
4.  Frontera 2000, Table 4       
     longitudinal study, men (∆ 12 yrs)             1985-6      1997-8 
     --  capil./fiber               1.39 ± 0.21                         1.08 ± 0.1 
            
5.  Ryan 2006, Fig 2D (ex)    
     vastus lateralis    19-25 yrs.                               62-72 yrs.      
     --  capil./mm2 vs. Type 1 fibers              240     200 
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Table 2.  Reduced Capillary Density in Skeletal Muscles of Young  vs. Aged Animals 
    
                 Young                                      Aged 
1.  Haidet 1991, Table 6   
     Beagle dogs, cap/µm2                                     2-3 yrs.                           10-14 yrs. 
      --   gastrocnemius               886 ± 49           718 ± 31 
      --  semitendinosus               895 ± 41                       658 ± 31 
      --  triceps                959 ± 47                       805 ± 52 
 
2.  Degens 1993, Fig.4 (ex) *             
     rat plantarus                 5 mo.           13 mo.            25 mo. 
     --  capil./mm2                                          1000                 850                     700 
  
3.  Rivard 1999, Fig. 5 (ex) *                          12 wks.                                       2 yrs. 
     --  mice hind limb, capil./mm2                          710               350 
                 6-8mo                                        4-5 yrs 
     --  rabbits hind limb, capil./mm2                                   170               130 
  
4.  Leosco 2007, Fig. 3  
     rat hind limb, capil./mm2                                 4 mo.                                         24 mo. 
     --  untrained                 590               300 
     --  trained     750               475 
 
 
* Data in some figures have been extrapolated from figures, as indicated by (ex).   
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Table 3.  Reduced Angiogenic Factors in Muscles of Young, Aged, & AD Subjects   
                  
            Young                               Aged 
1.   Drubaix 1998, Figs. 4,5 (ex )        
      ng/mg DNA of saphenous vein wall          20-40 yrs.      41-60 yrs.      61-82 yrs. 
      --  bFGF            180                 70                 50 
      --  PDGF                          70     45               30 
  
2.  Solerte 2002, abstract        
      VEGF released, pg/ml                            healthy (yrs. not stated)         AD & VAD 
      --  from monocytes                      296    125   
 
3.  Croley  2005, Fig. 2A (ex)               
     VEGF/B actin ratio, after exercise             22-28 yrs                              60-85 yrs 
     --  females gastrocnemius muscles                7.6                                        3.2 
  
4.  Ryan 2006, Fig. 4,5 (ex)                      
      vastus lateralis in men                              19-25 yrs.            62-72 yrs. 
      --  VEGF 18s mRNA, at rest        1.0       0.4 
      --  VEGF 18s mRNA , 4 hrs after exercise     3.4       1.8 
      --  VEGF protein, at rest         1.05                                      0.55 
      --  VEGF protein, 4 hrs after exercise            1.15                                      0.9 
 
 
 
* Data in some figures have been extrapolated from figures in text, as indicated by (ex).   
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Table 4.  Reduced Angiogenic factors in Skeletal Muscles of  Young  vs. Aged Animals     
   
        Young                          Aged 
1.  Rivard 1999, Figs. 8A&C  
     VEGF protein in ischemic muscle of rabbits    12 wks.         2 yrs.   
     --  Western blot, Fig. 8A                             young level                   reduced        
     --  immunostaining, Fig. 8C    young level                   reduced      
 
2.  Wagatsuma 2006, Fig. 2 (ex)       
     gastrocnemius muscle of mice                       2.5 mo.                       22 mo. 
     --  VEGF                  1.0                             0.7   
 
3.  Swift 1999, Table 1 
     muscle wound homogenates of mice             2-3 mo.                 22-24 mo. 
     --  VEGF …  before injury/wound           not detectable           -- 
                       day 5              116    65 
                       day 7                84                               43 
     --  FGF-2 … before injury                              27                               49 
                       day 5                       362           253 
      day 7                 407                             263 
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Table 5.  Physiological Angiogenesis in Muscles       
                        
5A.  PHYSICAL EXERCISE  … ↑ = increase, ↓ = decrease …  G20 = ca. age 20, G60 = ca. age 60 
 
      --  People … 15 studies … aerobic training and muscles  
 Andersen 1975, 1977 … ↑ CD by 50% 
 Brodal 1977 … ↑ CD …  corrected for fiber shrinkage: 305  425 
 Ingjer  1978, 1979 … female … ↑ CD: 1.39  1.79 (<0.005)  
 Denis 1986 … ↑ CD:  G20: 316  396 …  G60: 308  409 
 Hather 1991 … ↑ CD  
 Coggan 1992 … ↑ CD … less so in aged males & females  
 Hepple 1997 … ↑ CD 
 Richardson 1999 … ↑ VEGF/18s:  0.38 ±0.04  16.9 ±6.7  …  no effect with βFGF mRNA   
 Gustafsson 1999 … 3x ↑ VEGF & VEGF mRNA … FGF not increased  
 Gustafsson 2001, 2002 … 2-3x ↑ VEGF & VEGF mRNA 
 Ryan 2006 ... ↑ VEGF/18s …  less so in aged 
 Gavin 2007 … ↑ CD, ↑ VEGF … lesser increase in aged 
      --  Animals … 6  studies   
 Unger 1979 rats … swimming  ↑ myocardial capillary cell walls … no signif. ↑ in aged rats 
 Adolfsson 1981 rats … ↑ CD … skeletal muscle … less so in old rats 
 Breen 1996 rats … ↑ VEGF, ↑ TGF-β, ↑ βFGF … skeletal muscle 
 Gavin 2000 rats … ↑ receptor Flt for VEGF mRNA  … skeletal muscle  
 Amaral 2001 rats … ↑ CD … VEGF neutralizing Ab blocked angiogenesis … skeletal muscle 
 Lloyd 2003 rats … ↑ CD, ↑ VEGF … skeletal muscle 
5B. ELECTRICAL STIMULATION  --  Animals only … 10 studies in muscles 
 Brown 1976 rabbits … ↑ CD 
 Hudlicka 1982 rabbits … ↑ CD 
 Hang 1995 rats … 6x ↑ VEGF mRNA 
 Annex 1998 rabbits … 3x ↑ VEGF  
 Roca 1998 rats … 3x ↑ VEGF mRNA … no change in βFGF or TGF-β1 
 Skorjanc 1998 rabbits …  ↑ CD, ↑ VEGF mRNA 
 Kanno 1999 rats … ↑ CD, ↑ VEGF … ischemic hind limb    
 Milkiewicz 2001 rats … ↑ VEGF 
 Verhaeg 2001 rats … ↑ CD 
 Hudlicka 2002 rats/rabbits … ↑ CD, ↑ VEGF 
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Table 6.  Ischemic Hind Limbs, Grafts, Wounds, & Sponges Treated with Various AG Factors  
 
6A.  Ischemic hind limb model  … 5 studies … ↑ = increase       
--  Takeshita 1994, 1995 in rabbits … VEGF, IV bolus 1x    ↑ CD  
--  Rivard  1999 in rabbits, mice … VEGF, IV bolus 1x    ↑ CD 
--  Baffour 1992 in rabbits … rh bFGF, IM qd x2 wks    ↑ CD 
--  Yang 1996 in rats … bFGF, subQ pump x 14 days    ↑ CD 
--  Witzenbichler 1998 in rabbits … rh VEGF-C, IV bolus x1    ↑ CD 
 
6B.  Wounds  (full thickness skin, sponge/gel implants, bone graft) … 8 studies 
--  Eppley 1988 in rabbits … bone grafts … bFGF    ↑ vascularity & healing  
--  McGee 1988 in rats … skin wound … bFGF    “modest” ↑ healing  
--  Beck 1990 in pigs … skin wounds … rhTGF-β1    ↑ blood flow 
--  Greenhalgh 1990 in mice … skin wounds … rbFGF  &  rPDGF-BB    ↑ CD 
--  Tsuboi 1990 in diabetic mice … skin wounds … βFGF    ↑ CD & healing 
--  Puolakkainen 1995 in aged rats … skin wounds … TGF- β1    ↑ CD & healing  
--  Thompson 1988 in rats … gelatin sponges in skin with  aFGF    “significant angiogenesis” 
--  Dellian 1996 in mice … gel in skin chamber with VEGF & βFGF    ↑ CD 
 
aFGF = heparin binding growth factor   
PIGF = rPDGF-BB = platelet derived growth factor  
qd = every day 
rh = recombinant human  
VEGF = vascular endothelial growth factor  
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